

# Spain

Population 2016

46 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.28 (0.28–0.29)	0.61 (0.61–0.62)
Mortality (HIV+TB only)	0.053 (0.035–0.075)	0.11 (0.07–0.16)
Incidence (includes HIV+TB)	4.7 (4–5.5)	10 (8.7–12)
Incidence (HIV+TB only)	0.34 (0.29–0.41)	0.74 (0.62–0.88)
Incidence (MDR/RR-TB)**	0.23 (0.16–0.3)	0.5 (0.33–0.66)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.2 (0.17–0.23)	1.6 (1.4–1.9)	1.8 (1.6–2.1)
Males	0.22 (0.19–0.25)	2.7 (2.3–3.1)	2.9 (2.4–3.3)
Total	0.42 (0.35–0.48)	4.3 (3.7–5)	4.7 (4–5.5)

TB case notifications, 2016	
Total cases notified	4 877
Total new and relapse	4 734
- % tested with rapid diagnostics at time of diagnosis	20%
- % with known HIV status	
- % pulmonary	72%
- % bacteriologically confirmed among pulmonary	86%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	100% (87–120)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.07 (0.06–0.08)

TB/HIV care in new and relapse TB patients, 2016		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy			

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			170 (120–220)
Estimated % of TB cases with MDR/RR-TB	4.2% (2.9–5.8)	18% (9.4–30)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size			Success	Cohort
New cases registered in 2015				
Previously treated cases registered in 2015				
HIV-positive TB cases registered in 2015				
MDR/RR-TB cases started on second-line treatment in 2014				
XDR-TB cases started on second-line treatment in 2014				

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017	
National TB budget (US\$ millions)	

\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB